One part of the market has held on, another part seems to be falling apart. Over the last month or so the S&P 500 and Dow Jones Industrials have essentially moved sideways, but the Nasdaq and Russell 2000 have clearly trended lower. Tech …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …
What's the outlook for Gilead Sciences' stock? Over the short run, that question is next to impossible to answer. Over the long run, though, investors can project how well Gilead stock (or any other stock, for that matter) should perform with …
It was a busy week as well as weekend for the biotech sector. Highlights from last week include the approval of Gilead’s (GILD) hepatitis C virus (:HCV) treatment, Sovaldi, and that of Auxilium’s (AUXL) Xiaflex (Peyronie’s disease), a …
Genmab A/S : Genmab enters commercial license agreement with Gilead for DuoBody(R) Technology . Genmab is entitled to potential development, regulatory and sales milestones of up to USD 277 million . Agreement is not …